Phospholipase C-gamma 2 Couples Bruton's Tyrosine Kinase to the NF-kappa B Signaling Pathway in B Lymphocytes*

James B. Petro and Wasif N. KhanDagger

From the Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146

Received for publication, October 6, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Mutations in the gene encoding Bruton's tyrosine kinase (BTK) interfere with B cell proliferation and lead to an X-linked immunodeficiency in mice characterized by reduced B cell numbers. Recent studies have established that BTK transmits signals from the B cell antigen receptor (BCR) to transcription factor NF-kappa B, which in turn reprograms a set of genes required for normal B cell growth. We now demonstrate that induction of NF-kappa B via this pathway requires the intermediate action of the -gamma 2 isoform of phospholipase C (PLC-gamma 2), a potential phosphorylation substrate of BTK. Specifically, pharmacologic agents that block the action of either PLC-gamma 2 or its second messengers prevent BCR-induced activation of Ikappa B kinase. Moreover, activation of NF-kappa B in response to BCR signaling is completely abolished in B cells deficient for PLC-gamma 2. Taken together, these findings strongly suggest that PLC-gamma 2 functions as an integral component of the BTK/NF-kappa B axis following BCR ligation. Interference with this NF-kappa B cascade may account for some of the B cell defects reported for plc-gamma 2-/- mice, which develop an X-linked immunodeficiency-like phenotype.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

The generation and survival of B lymphocyte subpopulations is contingent upon the expression of a functional B cell antigen receptor complex (BCR)1 (1, 2). BCR engagement directs B cell biological responses by initiating biochemical signaling cascades involving the cytoplasmic protein tyrosine kinases Lyn, Syk, and BTK (3-5). BTK plays an integral role in transducing BCR-directed signals, because mutations in the btk gene result in the B cell deficiencies X-linked agammaglobulinemia (XLA) in man and X-linked immunodeficiency (xid) in mice (6-10). B cells from xid mice are defective in survival and proliferation, implicating BTK in these biological processes (10-12). However, the molecular mechanisms by which BTK effects B cell proliferation and survival are not well understood.

Like BTK, transcription factor NF-kappa B has been implicated in the regulation of genes essential for B cell responses including proliferation and survival (13-15). In resting cells, NF-kappa B is sequestered in the cytoplasmic compartment via its association with a family of inhibitory proteins, termed Ikappa Bs (16). Recent studies have identified a cytokine-inducible Ikappa B kinase complex (IKK) consisting of two catalytic (IKKalpha and IKKbeta ) and one regulatory subunit (IKKgamma ) (17). In response to NF-kappa B activating signals, IKK phosphorylates and targets Ikappa B for degradation (17). We and others (18, 19) have recently shown that BTK couples the BCR to IKK and NF-kappa B. However, the biochemical mechanism by which BTK activates NF-kappa B remains largely undefined.

BTK, in concert with the protein tyrosine kinase Syk and the adaptor protein BLNK, has recently been demonstrated to phosphorylate and activate PLC-gamma 2 (22-24). In response to BCR signals, PLC-gamma 2 catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate, generating inositol 1,4,5-trisphosphate and diacylglycerol. Inositol 1,4,5-trisphosphate induces the release of Ca2+ from intracellular stores, and diacylglycerol facilitates the activation of PKC isoenzymes (20, 21). Thus, BTK-dependent activation of PLC-gamma 2 is essential for BCR-initiated calcium fluxes (22). However, the functional consequences of PLC-gamma 2 signaling in the activation of nuclear factors that direct B cell responses are not known.

In this report, we provide two lines of evidence indicating that BCR-initiated activation of NF-kappa B is mediated by PLC-gamma 2. First, DT40 chicken B cells deficient for PLC-gamma 2 fail to translocate NF-kappa B to the nucleus upon BCR activation. Second, pharmacologic inhibition of PLC-gamma 2 or its second messengers prevents BCR-responsive activation of IKK and phosphorylation of Ikappa Balpha in primary B cells. These biochemical findings provide a potential molecular explanation for the B cell defects recently reported for plc-gamma 2-/- mice, which display an xid-like phenotype reminiscent of animals lacking functional BTK (10).


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Cells and Reagents-- The chicken B cell line DT40, DT40 cells deficient for either BTK or PLC-gamma 2 (DT40.BTK, DT40.PLC-gamma 2), or mutant DT40 cells reconstituted with either human BTK or PLC-gamma 2 (DT40.BTKR, DT40.PLC-gamma 2R) were a kind gift of Dr. Tomohiro Kurosaki, Riken Cell Bank, Japan (23, 24). DT40 cells were maintained as described previously and were cultured in low serum media (RPMI with 0.5% FCS, 0.05% chicken serum) for 8-12 h prior to stimulation (18).

Splenocytes and primary B lymphocytes were isolated from spleens of C57Bl6 mice. For phospho-Ikappa Balpha Western analyses, RBC-depleted splenocytes were cultured and stimulated as indicated. For IKK in vitro kinase assays, B cells were purified by a process of negative selection on an affinity chromatography column (Cedarlane, Ontario, Canada). The purity of B cells isolated in this manner was ~90-95% as verified by fluorescence-activated cell sorter analysis using anti-B220 and anti-IgM antibodies (PharMingen). All purifications were performed at 4 °C, and primary cells were used immediately upon purification.

All pharmacological reagents were purchased from Calbiochem. For inhibition of BCR signaling, cells were incubated with EGTA (5 mM), BAPTA-AM (20 nM), cyclosporin A (20 µg/ml), bisindolylmaleimide I (20 µM), or U-73122 (5 µM) for 30 min prior to and during stimulation. Except where indicated in the figure legends, DT40 B cells were either left unstimulated or stimulated with a 1:2 dilution of hybridoma supernatants containing anti-chicken IgM monoclonal antibody (M4) or PMA and ionomycin, 1 µM each. Purified B cells (3-5 × 106 cells per sample) were incubated with 10 µg/ml polyclonal goat anti-mouse IgM F(ab')2 fragments (Jackson ImmunoResearch), 10 µg/ml anti-mouse CD40 (PharMingen), or with PMA and ionomycin (1 µM each) at a cellular density of 2 × 106/ml in culture media (RPMI 1640 supplemented with 10% serum). To monitor any effects of serum on the activation of NF-kappa B, cells that were not stimulated were also incubated in medium containing 10% serum for the duration of stimulation.

Electrophoretic Mobility Shift Assays (EMSAs)-- Nuclear extracts were prepared and used in DNA-binding reactions as described previously (18). For EMSAs, an [alpha -32P]CTP- and [alpha -32P]ATP-labeled double-stranded oligonucleotide probe derived from the kappa B enhancer element of the IL-2Ralpha receptor promoter (5'-CAACGGCAGGGGAATTCCCCTCTCCTT-3') was used. To verify equal amounts and integrity of proteins in the nuclear extracts, a control oligonucleotide for NF-Y was used. DNA-binding reactions were resolved by PAGE and visualized by autoradiography.

Western Blot Analyses-- For Western blot analysis of RelA and c-Rel, nuclear extracts equivalent to 2 × 107 cells were denatured in Laemmli reducing buffer by boiling at 95 °C for 3 min, and the proteins were resolved by SDS-PAGE. Proteins were electrotransferred onto nitrocellulose membranes and subjected to immunoblotting with rabbit polyclonal antibodies against RelA, c-Rel, or SP1 as described previously (18). For Ikappa Balpha degradation assays, 4 × 106 cells/sample were preincubated for 30 min in medium containing 50 µM cycloheximide and then stimulated as indicated. Cell extracts were resolved by SDS-PAGE, transferred onto nitrocellulose membranes, probed with antibodies against chicken Ikappa Balpha (pp40; gift of C. Chen) and p38 MAPK (Santa Cruz Biotechnology), and detected using the ECL system. Western blot analyses of Ikappa Balpha phosphorylation were performed as above and probed with antibodies against mouse Ikappa Balpha (Santa Cruz Biotechnology) or phosphorylated Ser-32/Ser-36 Ikappa Balpha (Santa Cruz Biotechnology).

Plasmid Constructs and Luciferase Assays-- The kappa B reporter plasmid encoding firefly luciferase under the control of a promoter containing six consensus NF-kappa B binding sites (6kappa B) and a control vector containing a Renilla luciferase gene fused to a thymidine kinase promoter have been described previously (25).

The indicated DT40 cell lines were each cotransfected by electroporation (250 V, 960 microfarads, Bio-Rad Gene Pulser) with 5 µg of the 6kappa B reporter construct and 1 µg of the Renilla construct. 18 h post-transfection, cells were stimulated for 6 h with anti-IgM. Cells were harvested, and levels of both firefly and Renilla luciferase were determined using a Dual Luciferase Reporter Assay System (Promega). Levels of firefly luciferase expression were normalized against Renilla as a control for transfection efficiency.

In Vitro Kinase Assays-- In vitro kinase assays were performed on the cytosolic fraction of 5 × 106 B cells as described previously (18). Briefly, cell extracts from 0.5 × 106 cell equivalents were removed for Western blot analysis, and the remaining cell extract was subjected to immunoprecipitation with anti-IKKalpha plus anti-IKKbeta antibodies (Santa Cruz Biotechnology). The immunocomplexes were then resuspended in 20 µl of kinase buffer (20 mM HEPES, pH 7.2, MgCl2 (2 mM), MnCl2 (2 mM), dithiothreitol (1 mM), ATP (20 µM)) containing 1.0 µCi of [gamma -32P]ATP and 50 µg/ml wild type GST-Ikappa Balpha substrate. The reaction was allowed to continue for 30 min at 30 °C under agitation and then was terminated by the addition of 4× SDS sample buffer. The samples were resolved by 8% SDS-PAGE and stained with Coomassie Brilliant Blue to visualize the GST-Ikappa Balpha substrate. The gels were dried and exposed to x-ray film to visualize gamma -32P-phosphorylated GST-Ikappa Balpha .


    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

In prior studies, we established that BTK is required for nuclear translocation of NF-kappa B in BCR-stimulated B cells (18). However, the molecular mechanism by which BTK facilitates NF-kappa B activation is poorly defined. Recent findings suggest that BCR-directed nuclear translocation of NF-kappa B requires the activation of the calcium-responsive phosphatase calcineurin (26). To define further the mechanism employed by BTK to effect NF-kappa B activation, we investigated a role for calcium and calcineurin in BCR-responsive nuclear translocation of NF-kappa B in DT40 B cells.

The DT40 B cell system is amenable to genetic manipulation and has thus proven invaluable for biochemical analysis of BCR-signaling events (27). To determine whether calcium and calcineurin play a role in BCR-responsive activation of NF-kappa B in this cellular background, EMSA analyses were performed on nuclear extracts prepared from DT40 cells preincubated with pharmacological inhibitors of calcium, calcineurin, and PKCs. We used BAPTA-AM/EGTA to chelate intra- and extracellular calcium and cyclosporin A (CsA) to inhibit the calcium-responsive phosphatase calcineurin or bisindolylmaleimide (Bis I), a broad spectrum inhibitor of PKC isoenzymes (Fig. 1). We also treated DT40 cells with PMA and ionomycin, pharmacological agents known to activate NF-kappa B via IKK, as a positive control (28). As expected, BCR cross-linking or PMA/ionomycin treatment resulted in the rapid nuclear accumulation of NF-kappa B (compare lane 1 with 2 and 10). However, BCR-directed nuclear translocation of NF-kappa B was inhibited by treatment with BAPTA-AM/EGTA or CsA (lanes 3 and 4). Bis I treatment significantly, although not completely, inhibited this response (lane 5). However, preincubation with Bis in combination with either BAPTA-AM/EGTA or CsA resulted in a complete block in NF-kappa B nuclear translocation upon BCR activation (lanes 6 and 7). This result demonstrates that inhibition of either calcium or calcineurin and PKC completely abolishes BCR-directed activation of NF-kappa B in DT40 B cells.



View larger version (68K):
[in this window]
[in a new window]
 
Fig. 1.   A requirement for Ca2+, calcineurin, and PKC in BCR-directed activation of NF-kappa B. Pharmacological inhibition of BCR-responsive second messengers prevents BCR-directed nuclear translocation of NF-kappa B. DT40 cells were pretreated with EGTA/BAPTA-AM, cyclosporin A, and bisindolylmaleimide I and then were left unstimulated or stimulated as indicated. Nuclear extracts were used in EMSA. Autoradiograms were quantitated with Image Gauge software (Koshin graphics system), and levels of nuclear NF-kappa B were normalized against NF-Y. Quantitative results for each sample are reported as the percentage of NF-kappa B nucleoprotein complexes present relative to anti-IgM-treated B cells (lane 2).

Upon BCR ligation, BTK activates a distinct set of signal transducers to initiate downstream signaling events (3, 29). Of these, Akt, MAPK, and PLC-gamma 2 have the capability to activate NF-kappa B via IKK. Although both Akt and MAPK have been directly linked to IKK activation (30, 31), such a role has not been demonstrated for PLC-gamma 2. However, our finding that calcium and PKC are essential for nuclear translocation of NF-kappa B in BCR-stimulated DT40 cells implicates PLC-gamma 2 in this response (Fig. 1). Therefore, we next explored an involvement of PLC-gamma 2 in NF-kappa B nuclear translocation in B cells stimulated via the BCR.

To determine whether PLC-gamma 2 is critical for BCR-directed nuclear translocation of NF-kappa B, we used mutant chicken DT40 B cells lacking PLC-gamma 2 (DT40.PLC-gamma 2) along with BTK-deficient (DT40.BTK) and parental DT40 B cells. Cells were induced via the BCR, and their nuclear NF-kappa B content was assessed by EMSA (Fig. 2A). Although BCR cross-linking leads to a marked increase in nuclear NF-kappa B in DT40 cells (Fig. 2A, compare lanes 1 and 4), both DT40.PLC-gamma 2 and DT40.BTK B cells failed to demonstrate this response (Fig. 2A, compare lanes 2 and 5 and 3 and 6). However, PMA and ionomycin mobilized similar levels of nuclear NF-kappa B in all three cell types (Fig. 2A, lanes 7-9). These results strongly suggest that like BTK, PLC-gamma 2 plays an essential role in the transmission of BCR signals to activate NF-kappa B.



View larger version (31K):
[in this window]
[in a new window]
 
Fig. 2.   BCR-initiated activation of NF-kappa B is blocked in PLC-gamma 2-deficient (DT40.PLC-gamma 2) B cells similar to that of BTK-deficient (DT40.BTK) B cells. A, EMSA analysis of nuclear NF-kappa B in DT40, DT40.PLC-gamma 2, and DT40.BTK B cells. Cells were incubated in the presence or absence of anti-IgM (lanes 1-6) or PMA/ionomycin (lanes 7-9), and nuclear extracts were used in EMSA. B, time course of NFkappa B activation in DT40 and DT40.PLC-gamma 2 B cells in response to BCR stimulation. Nuclear extracts and EMSA were performed as in A. C, EMSA analysis of nuclear NF-kappa B from DT40, DT40.PLC-gamma 2 B cells reconstituted with human PLC-gamma 2 (DT40.PLC-gamma 2R), and DT40.BTK B cells reconstituted with human BTK (DT40-BTKR). Cells were either not stimulated or stimulated with anti-IgM. Nuclear extracts were isolated, and EMSA reactions were performed as described in "Materials and Methods." D, reconstitution of PLC-gamma 2 and BTK restores BCR-directed activation of NF-kappa B in DT40.PLC-gamma 2 and DT40.BTK B cells. Indicated B cells were cotransfected with an NF-kappa B firefly luciferase reporter plasmid and a Renilla luciferase plasmid to normalize for transfection efficiency. After culture for 18 h, cells were stimulated with anti-IgM and then assayed for reporter gene expression as described under "Experimental Procedures." Results are reported as the mean fold induction of luciferase in stimulated relative to unstimulated cells.

To ascertain whether the observed defect was due to delayed kinetics of NF-kappa B activation, we compared BCR-responsive nuclear translocation of NF-kappa B in DT40.PLC-gamma 2 cells with that in DT40 B cells over a period of 4 h (Fig. 2B). Upon BCR cross-linking, DT40 B cells rapidly translocated NF-kappa B to the nucleus and maintained elevated levels up to 4 h after activation. In contrast, nuclear levels of NF-kappa B did not increase in DT40.PLC-gamma 2 B cells at any time point within that period (Fig. 2B, compare lanes, 1, 3, 5, 7, and 9 with 2, 4, 6, and 8). To verify further that the NF-kappa B activation defect in DT40.PLC-gamma 2 B cells was due to PLC-gamma 2 deficiency, reconstitution experiments were performed. In response to BCR engagement, DT40.PLC-gamma 2 B cells expressing wild type human PLC-gamma 2 (DT40.PLC-gamma 2R (23)) were capable of NF-kappa B nuclear translocation as determined by EMSA and a NF-kappa B responsive luciferase reporter assay (Fig. 2, C and D). These data strongly suggest that PLC-gamma 2 is critical for transmission of BCR-dependent signals that lead to the nuclear translocation of NF-kappa B.

Members of the NF-kappa B/Rel family of proteins include p50/NF-kappa B1, p52/NF-kappa B2, RelA, c-Rel, and RelB, which have the capacity to form either homo- or heterodimers (16). NF-kappa B dimers containing the Rel family proteins RelA or c-Rel have been demonstrated to be the principal transactivating species activated in response to BCR engagement in B cells (35). We previously demonstrated that RelA and c-Rel fail to undergo nuclear translocation upon BCR stimulation in BTK-deficient B cells. To test whether BTK-mediated RelA and c-Rel nuclear translocation requires PLC-gamma 2, we compared the ability of DT40.PLC-gamma 2, DT40.BTK, and DT40 B cells to translocate these subunits to the nucleus upon BCR-cross-linking (Fig. 3, A and B). Immunoblotting of nuclear extracts from unactivated (lanes 1-3), anti-IgM stimulated (lanes 4-6), and PMA/ionomycin treated (lanes 7-9) cells with Rel subunit-specific antibodies revealed that nuclear accumulation of both RelA and c-Rel occurs in DT40 B cells following BCR stimulation (Fig. 3, A and B, lanes 1 and 4). In contrast, BCR-responsive nuclear translocation of RelA and c-Rel is not observed in either DT40.PLC-gamma 2 or DT40.BTK B cells. Treatment with PMA/ionomycin induced nuclear translocation of both Rel species (Fig. 3, A and B, lanes 7-9) in all three cell lines. Furthermore, the observed differences in Rel subunit translocation are not attributable to either variation in total protein content of the nuclear extracts or their integrity, because similar amounts of the constitutively expressed transcription factor SP1 are detectable in all samples (Fig. 3, A and B, lower panels). Thus, BCR-directed nuclear translocation of RelA and c-Rel is PLC-gamma 2-dependent.



View larger version (79K):
[in this window]
[in a new window]
 
Fig. 3.   PLC-gamma 2 is required for BCR-directed nuclear translocation of c-Rel and RelA. Western blot analysis of RelA levels in nuclear extracts isolated from DT40, DT40.PLC-gamma 2, or DT40.BTK B cells is shown. Cells were either unstimulated (lanes 1-3), stimulated with anti-IgM (lanes 4-6), or with PMA/ionomycin (lanes 7-9). Nuclear extracts were prepared and used in Western analyses as described under "Experimental Procedures." Blots were stripped and reprobed with an antibody against the constitutive nuclear factor SP-1 to verify extract integrity (lower panel). B, Western blot analysis of c-Rel nuclear levels was performed as in A.

NF-kappa B dimers are found in the cytoplasm of quiescent cells, bound to members of a family of inhibitory molecules termed Ikappa Bs. BCR-induced nuclear translocation of NF-kappa B is contingent upon the phosphorylation and proteolytic degradation of Ikappa Balpha , a process that requires BTK. We compared the ability of DT40.PLC-gamma 2 B cells with DT40.BTK and DT40 B cells to degrade Ikappa Balpha in response to BCR activation. Cells were incubated with anti-IgM antibodies or PMA and ionomycin for indicated periods, and cytoplasmic extracts were immunoblotted for chicken Ikappa Balpha (Fig. 4, upper panel). As expected, DT40 B cells rapidly degraded Ikappa Balpha upon BCR activation. Consistent with the results shown in Fig. 2, DT40.PLC-gamma 2 B cells failed to degrade Ikappa Balpha in response to BCR stimulation (Fig. 4, compare lanes 1-4 with 6-9 and 11-14). All three cell lines efficiently degraded Ikappa Balpha in response to treatment with PMA and ionomycin. Therefore, loss of PLC-gamma 2 does not affect the downstream components necessary for Ikappa Balpha degradation. These results demonstrate that BCR-directed degradation of Ikappa Balpha specifically requires PLC-gamma 2.



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 4.   PLC-gamma 2 is critical for BCR-directed degradation of Ikappa Balpha . Western blot analysis of Ikappa Balpha in cytosolic fractions from DT40 (lanes 1-5), DT40.PLC-gamma 2 (lanes 6-10), and DT40.BTK (lanes 11-15) B cells is shown. Cells were translationally arrested prior to stimulation by preincubation with cycloheximide. Cells were then stimulated for the indicated times with anti-IgM or PMA/ionomycin. Cytoplasmic extracts were used for Western analysis as described (18) with antisera against Ikappa Balpha (pp40). The blot was stripped and reprobed with an antibody against p38 MAPK to verify the protein content and integrity.

Prior biochemical studies have identified several NF-kappa B agonists that converge on IKKalpha and IKKbeta including TNF and IL-1 (17). Additionally, we have recently established that BCR-initiated activation of NF-kappa B by BTK proceeds via IKK (18). To extend our finding that PLC-gamma 2 is required for BCR-directed nuclear translocation of NF-kappa B, we explored a role for PLC-gamma 2 in IKK activation. We tested whether pharmacological agents that block PLC-gamma 2 and its second messengers could prevent BCR-induced activation of IKK in primary B cells (Fig. 5A). In response to activation signals via the BCR or CD40, or treatment with PMA, IKK enzymatic activity was significantly increased as determined by in vitro kinase assays using recombinant GST-Ikappa Balpha as the substrate (Fig. 5A, compare lane 1 with 2, 7, and 8). In contrast, incubation of B cells with either the PLC-gamma -specific inhibitor (U-73122) or inhibitors of its second messengers (BAPTA-AM/EGTA, CsA, or Bis I) prior to BCR stimulation abolished this activity (Fig. 5A, lanes 3-6). These data implicate PLC-gamma 2, calcium, calcineurin, and PKC in IKK activation upon BCR ligation. Moreover, they verify the role of these signaling molecules in BCR-responsive activation of IKK in a physiologically relevant background.



View larger version (50K):
[in this window]
[in a new window]
 
Fig. 5.   PLC-gamma 2 and its effectors are essential for BCR-responsive activation of IKK and Ikappa Balpha phosphorylation in primary splenic B cells. A, EGTA/BAPTA-AM, CsA, or Bis I impede BCR-induced IKK activation. IKK in vitro kinase assay was performed on purified primary B cells. Purified B cells were preincubated with inhibitors and then either left unstimulated or stimulated as indicated. Cytosolic extracts were immunoprecipitated with antibodies against IKKalpha and IKKbeta , and the resulting immunocomplexes were subjected to in vitro kinase assays containing [gamma -32P]ATP and GST-Ikappa Balpha as the substrate. Kinase assays were resolved by SDS-PAGE and subjected to autoradiography. The immunoblot with IKKbeta was performed with 10% of the cell extract used in the in vitro kinase assay to monitor steady state levels of IKKbeta . B, EGTA/BAPTA-AM, CsA, or Bis I prevent BCR-induced Ikappa Balpha Ser-32/Ser-36 phosphorylation. Western blot analysis of cytosolic extracts from splenocytes is shown. Cells were preincubated with the indicated inhibitors and then stimulated as in A. Cell lysates were used in Western analysis as in Fig. 3. Phosphorylated Ikappa Balpha was revealed using an antibody directed against phosphorylated serine residues (32 and 36) of Ikappa Balpha (Santa Cruz Biotechnology). The blot was stripped and reprobed with an anti-Ikappa Balpha antibody.

To confirm this observation, we performed Western blot analyses of cytosolic fractions from BCR-, CD40-, or PMA-stimulated splenocytes using an antibody directed against Ser-32/Ser-36-phosphorylated Ikappa Balpha (Fig. 5B, upper panel). Stimulation via either the BCR or CD40 induced phosphorylation of Ikappa Balpha (Fig. 5B, compare lanes 1, 2, and 6). BCR-responsive Ikappa Balpha phosphorylation was blocked by pretreatment with either BAPTA-AM/EGTA, CsA, or Bis I (Fig. 5B, lanes 3-5). Also, PMA stimulation resulted in Ikappa Balpha phosphorylation that was abrogated by pretreatment with the PKC inhibitor Bis I (Fig. 5B, lanes 7 and 8). These observations implicate PLC-gamma 2, calcium, and PKC in BCR-responsive activation of IKK and phosphorylation of Ikappa Balpha . Moreover, the observation that cells pretreated with CsA fail to activate IKK upon BCR cross-linking identifies calcineurin as a critical mediator of this response. This observation is consistent with the recent finding that calcineurin and PKCs synergize to induce IKK activation in T cells (28). Collectively, these data suggest that PLC-gamma 2 is likely to mediate BCR-responsive activation of IKK, phosphorylation of Ikappa Balpha , and nuclear translocation of NF-kappa B.

We have found that PLC-gamma 2 and its downstream signals are essential for BCR-directed activation of IKK and NF-kappa B. Prior studies in BCR-stimulated B cells have revealed that PLC-gamma 2 is activated via the concerted actions of BTK, Syk, and BLNK (3, 32). Therefore, it is likely that PLC-gamma 2 is the principal BTK signal transducer for BCR-directed activation of IKK and NF-kappa B. Further investigation is required to determine whether additional BTK targets, including Akt and MAPK, synergize with PLC-gamma 2 to effect nuclear translocation of NF-kappa B in BCR-stimulated B cells. However, the placement of PLC-gamma 2 in the BCR/BTK/NF-kappa B signaling pathway provides the first potential molecular explanation for the similar xid-like B cell deficiencies displayed by plc-gamma 2-/- and btk-/- mice (10, 33).


    ACKNOWLEDGEMENTS

We thank David Strayhorn for technical advice and Drs. Dean Ballard, Eugene Oltz, Sebastian Joyce, and Jacek Hawiger for helpful discussions in the preparation of this manuscript.


    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Microbiology and Immunology, Vanderbilt University school of Medicine, Nashville, TN 37232-0146. Tel.: 615-343-5632; Fax: 615-343-7392; E-mail: Khanwn@ctrvax.vanderbilt.edu.

Published, JBC Papers in Press, October 19, 2000, DOI 10.1074/jbc.M009137200


    ABBREVIATIONS

The abbreviations used are: BCR, B cell antigen receptor; xid, X-linked immunodeficiency; BTK, Bruton's tyrosine kinase; PLC-gamma 2, phospholipase C-gamma 2; NF-kappa B, nuclear factor-kappa B; IKK, Ikappa B kinase; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; Bis I, bisindolylmaleimide I; CsA, cyclosporin A; BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester; GST, glutathione S-transferase; EMSA, electrophoretic mobility shift assays; PAGE, polyacrylamide gel electrophoresis; MAPK, mitogen-activated protein kinase.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES


1. Lam, K. P., Kuhn, R., and Rajewsky, K. (1997) Cell 90, 1073-1083[Medline] [Order article via Infotrieve]
2. Rajewsky, K. (1996) Nature 381, 751-758[CrossRef][Medline] [Order article via Infotrieve]
3. Fruman, D. A., Satterthwaite, A. B., and Witte, O. N. (2000) Immunity 13, 1-3[Medline] [Order article via Infotrieve]
4. Yang, W. C., Collette, Y., Nunes, J. A., and Olive, D. (2000) Immunity 12, 373-382[Medline] [Order article via Infotrieve]
5. Campbell, K. S. (1999) Curr. Opin. Immunol. 11, 256-264[CrossRef][Medline] [Order article via Infotrieve]
6. Vetrie, D., Vorechovsky, I., Sideras, P., Holland, J., Davies, A., Flinter, F., Hammarstrom, L., Kinnon, C., Levinsky, R., Bobrow, M.,., Smith, C. I., and Bently, D. R. (1993) Nature 361, 226-233[CrossRef][Medline] [Order article via Infotrieve]
7. Tsukada, S., Saffran, D. C., Rawlings, D. J., Parolini, O., Allen, R. C., Klisak, I., Sparkes, R. S., Kubagawa, H., Mohandas, T., Quan, S., Belmont, B. W., Cooper, M. D., Conley, M. E., and Witte, O. N. (1993) Cell 72, 279-290[Medline] [Order article via Infotrieve]
8. Thomas, J. D., Sideras, P., Smith, C. I., Vorechovsky, I., Chapman, V., and Paul, W. E. (1993) Science 261, 355-358
9. Rawlings, D. J., Saffran, D. C., Tsukada, S., Largaespada, D. A., Grimaldi, J. C., Cohen, L., Mohr, R. N., Bazan, J. F., Howard, M., Copeland, N. G., Jenkins, N. A., and Witte, O. N. (1993) Science 261, 358-361
10. Khan, W. N., Alt, F. W., Gerstein, R. M., Malynn, B. A., Larsson, I., Rathbun, G., Davidson, L., Muller, S., Kantor, A. B., Herzenberg, L. A., Rosen, F. S., and Sideras, P. (1995) Immunity 3, 283-299[Medline] [Order article via Infotrieve]
11. Anderson, J. S., Teutch, M., Dong, Z., and Wortis, H. H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10966-10971[Abstract/Free Full Text]
12. Solvason, N., Wu, W. W., Kabra, N., Lund-Johansen, F., Roncarolo, M. G., Behrens, T. W., Grillot, D. A., Nunez, G., Lees, E., and Howard, M. (1998) J. Exp. Med. 187, 1081-1091[Abstract/Free Full Text]
13. Bendall, H. H., Sikes, M. L., Ballard, D. W., and Oltz, E. M. (1999) Mol. Immunol. 36, 187-195[CrossRef][Medline] [Order article via Infotrieve]
14. Grumont, R. J., Rourke, I. J., O'Reilly, L. A., Strasser, A., Miyake, K., Sha, W., and Gerondakis, S. (1998) J. Exp. Med. 187, 663-674[Abstract/Free Full Text]
15. Kontgen, F., Grumont, R. J., Strasser, A., Metcalf, D., Li, R., Tarlinton, D., and Gerondakis, S. (1995) Genes Dev. 9, 1965-1977[Abstract]
16. Baldwin, A. S., Jr. (1996) Annu. Rev. Immunol. 14, 649-683[CrossRef][Medline] [Order article via Infotrieve]
17. Zandi, E., and Karin, M. (1999) Mol. Cell. Biol. 19, 4547-4551
18. Petro, J. B., Rahman, S. M., Ballard, D. W., and Khan, W. N. (2000) J. Exp. Med. 191, 1745-1754[Abstract/Free Full Text]
19. Bajpai, U. D., Zhang, K., Teutsch, M., Sen, R., and Wortis, H. H. (2000) J. Exp. Med. 191, 1735-1744[Abstract/Free Full Text]
20. Berridge, M. J. (1993) Nature 361, 315-325[CrossRef][Medline] [Order article via Infotrieve]
21. Imboden, J. B., and Stobo, J. D. (1985) J. Exp. Med. 161, 446-456[Abstract]
22. Fluckiger, A. C., Li, Z., Kato, R. M., Wahl, M. I., Ochs, H. D., Longnecker, R., Kinet, J. P., Witte, O. N., Scharenberg, A. M., and Rawlings, D. J. (1998) EMBO J. 17, 1973-1985[Free Full Text]
23. Takata, M., Homma, Y., and Kurosaki, T. (1995) J. Exp. Med. 182, 907-914[Abstract]
24. Takata, M., and Kurosaki, T. (1996) J. Exp. Med. 184, 31-40[Abstract]
25. Chen, C. L., Yull, F. E., and Kerr, L. D. (1999) Biochem. Biophys. Res. Commun. 257, 798-806[CrossRef][Medline] [Order article via Infotrieve]
26. Venkataraman, L., Burakoff, S. J., and Sen, R. (1995) J. Exp. Med. 181, 1091-1099[Abstract]
27. Kurosaki, T. (1999) Annu. Rev. Immunol. 17, 555-592[CrossRef][Medline] [Order article via Infotrieve]
28. Trushin, S. A., Pennington, K. N., Algeciras-Schimnich, A., and Paya, C. V. (1999) J. Biol. Chem. 274, 22923-22931[Abstract/Free Full Text]
29. Satterthwaite, A. B., Li, Z., and Witte, O. N. (1998) Semin. Immunol. 10, 309-316[CrossRef][Medline] [Order article via Infotrieve]
30. Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., and Donner, D. B. (1999) Nature 401, 82-85[CrossRef][Medline] [Order article via Infotrieve]
31. Romashkova, J. A., and Makarov, S. S. (1999) Nature 401, 86-90[CrossRef][Medline] [Order article via Infotrieve]
32. Rawlings, D. J. (1999) Clin. Immunol. 91, 243-253[CrossRef][Medline] [Order article via Infotrieve]
33. Wang, D., Feng, J., Wen, R., Marine, J. C., Sangster, M. Y., Parganas, E., Hoffmeyer, A., Jackson, C. W., Cleveland, J. L., Murray, P. J., and Ihle, J. N. (2000) Immunity 13, 25-35[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.